Across TCGA pan-cancer cohorts, VCX2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated VCX2 data layer compared with 17 for mass-spec protein.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher VCX2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated VCX2 expression acts as an unfavorable survival marker.
READ are the cancer types where VCX2 Mutation most reproducibly stratifies survival.